#### 1 Neuro-COVID long-haulers exhibit broad dysfunction in T cell memory generation and

#### 2 responses to vaccination

- 3 Lavanya Visvabharathy<sup>1\*¶</sup>, Barbara Hanson<sup>1,3</sup>, Zachary Orban<sup>1</sup>, Patrick H. Lim<sup>1</sup>, Nicole Palacio<sup>2</sup>,
- 4 Rishi Jain<sup>1</sup>, Eric Michael Liotta<sup>1</sup>, Pablo Penaloza-MacMaster<sup>2</sup>, Igor J. Koralnik<sup>1\*</sup>
- <sup>5</sup> <sup>1</sup>Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern
- 6 University, Chicago IL 60611 USA
- <sup>7</sup> <sup>2</sup>Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern
- 8 University, Chicago IL 60611 USA
- <sup>3</sup>Rush Medical College, Chicago IL 60612 USA

- 11 \*Corresponding authors: Igor J. Koralnik, M.D.: <u>igor.koralnik@northwestern.edu</u>;
- 12 Lavanya Visvabharathy, Ph.D: <u>lavanya.visvabharathy@northwestern.edu</u>
- 13 ¶ Lead contact: Lavanya Visvabharathy, Ph.D

# 14 Summary

15	The high prevalence of post-acute sequelae of SARS-CoV-2 infection (PASC) is a significant
16	health concern. In particular, virus-specific immunity in patients who suffer from chronic
17	neurologic symptoms after mild acute COVID remain poorly understood. Here, we report that
18	neuro-PASC patients have a specific signature composed of humoral and cellular immune
19	responses that are biased towards different structural proteins compared to healthy COVID
20	convalescents. Interestingly, the severity of cognitive deficits or quality of life markers in neuro-
21	PASC patients are associated with reduced effector molecule expression in memory T cells.
22	Furthermore, we demonstrate that T cell responses to SARS-CoV-2 mRNA vaccines are
23	aberrantly elevated in longitudinally sampled neuro-PASC patients compared with healthy
24	COVID convalescents. These data provide a framework for the rational design of diagnostics and
25	predictive biomarkers for long-COVID disease, as well as a blueprint for improved therapeutics.
26	Keywords: COVID-19 immunity, T cell memory, neuro-PASC, long-COVID, vaccine-induced
27	immunity

# 28 Introduction

29	SARS-CoV-2 is the causative agent of a worldwide pandemic that started in Wuhan,
30	China in December, 2019. There have been more than 200 million cases and over 4 million
31	deaths globally attributable to COVID-19 disease (Center, 2021). Although highly effective
32	vaccines are now used to prevent severe disease and death caused by SARS-CoV-2, long-term
33	sequelae of SARS-CoV-2 infection are increasingly becoming an important medical concern.
34	SARS-CoV-2 infection is associated with presentations ranging from asymptomatic
35	carriage to severe multi-organ dysfunction (Li et al., 2020; Liguori et al., 2020; Syed et al.,
36	2020). Globally, the estimated fatality rate following SARS-CoV-2 infection is approximately 1-
37	2%, but not all patients recover to their baseline states (Higgins et al., 2020). "Long COVID"
38	affects an estimated 10-40% of all infected people and includes symptoms persisting more than
39	28 days after diagnosis of SARS-CoV-2 infection, termed "post-acute sequelae of SARS-CoV-2
40	infection" or PASC (Ladds et al., 2020; Vehar et al., 2021). Greater than two-thirds of
41	hospitalized COVID-19 patients experience ongoing fatigue, breathlessness, and psychiatric
42	issues such as post-traumatic stress disorder (PTSD) 4-8 weeks after discharge (Halpin et al.,
43	2021). However, the vast majority of people with COVID experience mild disease not requiring
44	hospitalization, and more than half of these have symptoms persisting more than 4 months after
45	acute infection (Petersen et al., 2020). Many people who survived Middle-East respiratory virus
46	(MERS) and the original SARS-CoV pandemic also experienced PTSD and neurological
47	impairments up to 3.5 years after acute infection (Ahmed et al., 2020; Lam et al., 2009). More
48	recent studies on recovered COVID-19 patients showed significant cognitive deficits in attention,
49	working memory, and emotional processing months after acute infection had resolved
50	(Hampshire, 2021). Here, we focus on a cohort of mostly non-hospitalized long-COVID patients

51	presenting with neurological symptoms ("neuro-PASC") who exhibit a reduction in quality of
52	life with regards to cognitive and fatigue parameters (Graham et al., 2021).
53	Numerous studies suggest that a robust T cell response is necessary for viral clearance in
54	infected individuals. In particular, CD4 <sup>+</sup> T cell responses directed against the Spike protein were
55	found in 100% of healthy COVID convalescents, while 70% displayed Spike-specific $CD8^+$ T
56	cell responses (Grifoni et al., 2020). Another study found that memory T cells cross-reactive to
57	SARS-CoV-2 nucleocapsid (N) protein persisted in people exposed to SARS-CoV up to 17 years
58	after the epidemic of 2003 (Le Bert et al., 2020). Post-mortem autopsies of COVID-19 patients
59	have shown that innate immune cells but not lymphocytes are enriched in lung infiltrate, and that
60	these patients exhibit impaired germinal center formation in lung draining lymph nodes (Duan et
61	al., 2020). Additional studies have shown that CD8 <sup>+</sup> T cell depletion after SARS-CoV-2
62	infection of rhesus macaques impairs anamnestic responses, suggesting a role for T cell memory
63	in long-term immunity to SARS-CoV-2 infection (McMahan et al., 2021).
64	Most studies on T cell responses to SARS-CoV-2 have focused on acutely symptomatic
65	individuals. However, adaptive immune responses in patients who remain chronically
66	symptomatic remain largely unexplored. Our studies indicate that neuro-PASC patients ("CN")
67	had hypo-functional Ag-specific CD8+ T cell memory responses SARS-CoV-2 compared with
68	healthy convalescents ("CC") and enhanced reactivity to N and M proteins compared with CC
69	subjects. The severity of cognitive deficits and quality of life markers were associated with
70	enhanced polarization in cytolytic granule expression in memory T cell subsets. Finally, we
71	demonstrate that T cell responses to SARS-CoV-2 vaccination are more robust and display
72	aberrant kinetics in neuro-PASC patients compared with control groups. Together, these data
73	demonstrate a wide-scale dysfunction in SARS-CoV-2 T cell memory in neuro-PASC long-

- hauler patients, with important implications for both appropriate diagnostic and vaccination
- 75 strategies.

## 76 **Results**

### 77 Clinical characteristics of neuro-PASC patients

78	We enrolled a total of 111 participants prior to SARS-CoV-2 vaccination drawn from the
79	neuro-COVID-19 outpatient clinic at Northwestern Memorial Hospital or from the surrounding
80	Chicago area. This included 56 neuro-PASC "CN" patients (confirmed RT-PCR+ or anti-SARS-
81	CoV-2 Spike IgG+) meeting Infectious Disease Society of America clinical criteria for COVID-
82	19 starting after February 2020 and had neurologic symptoms lasting at least 6 weeks post-
83	infection, as previously reported (Graham et al., 2021). Among those, 48 (86%) were never
84	hospitalized for pneumonia or hypoxemia. We additionally recruited 24 healthy COVID
85	convalescents without lasting symptoms (RT-PCR+ or seropositive for anti- SARS-CoV-2 Spike
86	RBD IgG, "CC"); and 31 healthy controls who were RT-PCR- and seronegative for SARS-CoV-
87	2 Spike-IgG ("HC"; study description in Fig. 1A).
88	CN patients displayed a constellation of neurological symptoms similar to those
89	previously reported by our group and in other studies (Fig. 1B). In addition, we utilized
90	standardized methods to quantify their quality of life and cognitive disturbances relative to
91	healthy convalescents. Results from the patient reported outcomes information system
92	(PROMIS-57) survey (Tang et al., 2019) showed that CN patients scored significantly lower on
93	physical function and higher on anxiety, depression, pain and other metrics compared with CC
94	subjects or the national average (Fig. 1C). NIH toolbox tests administered to CN patients to
95	assess their cognitive function (Weintraub et al., 2013) showed CN patients had significantly
96	lower T scores in the attention module, which was indicative of cognitive dysfunction relative to
97	the national average (Fig. 1D).

#### 98 *Neuro-PASC is associated with a distinct immunodominance hierarchy.*

99	To determine whether neuro-PASC included alterations in the magnitude and/or
100	specificity of Ag-specific T cell responses in CN patients, we performed ELISPOT for SARS-
101	CoV-2-specific T cells. PBMC from each subject were cultured in the presence of peptide pools
102	derived from spike (S), nucleocapsid (N), or membrane (M) proteins of SARS-CoV-2 (Fig. S1).
103	The magnitude and specificity of both IFN- $\gamma$ and IL-2 responses to S sub-pools were similar
104	between CN and CC subjects (Fig. 2A-B). However, CN subjects produced high levels of IFN-γ
105	against all sub-pools of N and M proteins, while CC subjects had a specificity for the N1 pool
106	and lower responses against all M pools (Fig. 2C-D), indicative of different immunodominance
107	hierarchies between groups. No significant differences were found in IL-2 production, and
108	healthy controls exhibited some response to N pools likely caused by cross-reactivity with
109	endemic coronaviruses (Fig. 2E-F). Antibody titers against the Spike receptor-binding domain
110	(RBD) did not differ between CN and CC groups (Fig. 2G). Interestingly, high IgG titers did not
111	correlate with the magnitude of the IFN- $\gamma$ T cell response against S2 or S3 peptide pools
112	comprising the 2 halves of the Spike RBD (Fig. S2).

113 CD4<sup>+</sup> Tfh cells display opposing reactivity to SARS-CoV-2 N- and M-proteins in neuro-PASC vs.
114 healthy COVID convalescents

115 RNA-Seq analysis of CD4<sup>+</sup> T cells from hospitalized and non-hospitalized COVID-19 116 patients showed that severe disease is associated with elevated CD4<sup>+</sup> T follicular helper (Tfh) 117 proportions relative to patients with mild disease (Meckiff et al., 2020). We sought to determine 118 whether Tfh responses (gating in Fig. S3) that prime antibody production from plasma B cells 119 could similarly differentiate neuro-PASC CN patients from CC individuals. Immunophenotyping 120 showed that there were no differences in total percentages of T cell subsets, including Tfh cells,

121 between groups (Fig. S4). The activation-induced marker (AIM) assay has been previously used to detect TCR-mediated activation of T cells (Grifoni et al., 2020) and we used this method to 122 investigate Tfh cell activation (gating for Tfh cells in Fig. S3). N protein-specific 123 124 CD134<sup>+</sup>CD137<sup>+</sup> (AIM<sup>+</sup>) CD4 Tfh cells were significantly elevated in CN compared with CC subjects, while the opposite trend was observed in M protein-specific activation (Fig. 3A-B). No 125 differences were seen in Tfh activation between CN and CC groups across Spike peptide pools 126 (Fig. 3B). The magnitude of N- and M-specific Tfh cell activation did not correlate with the time 127 since acute infection in either CN or CC patients (Fig. 3C-D) despite reports showing that 128 129 antibody titers against N protein decrease rapidly post-infection (Van Elslande et al., 2021) which would presumably lead to decreased N-specific Tfh cell activation over time. N-specific 130 IgG titers were significantly elevated in CN compared with CC subjects (Fig. 3E), consistent 131 132 with the enhanced N-specific CD4<sup>+</sup> Tfh cell activation shown in 3B. Similar to Tfh cells, there was no correlation between anti-N IgG titers and time post-symptom onset for either CN or CC 133 subjects (Fig. S5A). Studies have shown that IgG titers against N protein decline to undetectable 134 levels in 40% of COVID convalescents within 4 months (Muecksch et al., 2021). We largely did 135 not observe this decline in CN patients despite collecting their blood samples an average of 193 136 137 days post-symptom onset (Fig. 1B).

138 CD4<sup>+</sup> T cell polyfunctionality to Spike protein differs in neuro-PASC vs. healthy COVID
139 convalescents

Cytotoxic CD4<sup>+</sup> T cells acquire the ability to produce cytolytic granules upon activation
 with cognate viral antigen (Goubard et al., 2015; Sledzinska et al., 2020). Viral infections
 specifically induce expansion of the memory CD4<sup>+</sup> T effector memory cells re-expressing
 CD45RA (TEMRA) population that secrete copious amounts of cytolytic granules upon antigen

144	encounter (Tian et al., 2017). We therefore investigated whether Ag-specific production of
145	multiple granzymes and cytokines in CD4 <sup>+</sup> T cells were altered between groups. While CN and
146	HC groups maintained polyfunctionality and polarization, CC subjects had significantly more
147	polyfunctional CD4 <sup>+</sup> T cells producing granzymes A, B, and M after Spike pool stimulation
148	(category 2 in yellow, Fig. 3F). A heatmap quantifying this effect showed that CC had a 2-fold
149	elevation in category 2 effector molecules over CN subjects (Fig. 3G). This data suggests that
150	cytotoxic responses to Spike protein in CD4 <sup>+</sup> T cells from healthy COVID-19 convalescents
151	significantly differ from those experiencing chronic neurologic symptoms.
152	CD8 <sup>+</sup> memory T cell functionality in neuro-PASC patients
153	CD8 <sup>+</sup> memory T cells are crucial for protection from recurrent viral infections (Mockus
154	et al., 2019). Studies have shown that memory CD8 <sup>+</sup> cells can persist for several years after
155	patient exposure to SARS-CoV (Chen et al., 2005) and that acute mild disease induces stronger
156	Ag-specific CD8 <sup>+</sup> memory responses than severe disease (Peng et al., 2020). However, little is
157	known about whether $CD8^+$ memory differs in neuro-PASC long-haulers vs. healthy COVID
158	convalescents months after acute infection resolves. To address this, we probed the dynamics of
159	CD8 <sup>+</sup> TEM, TCM, and TEMRA activation in CN, CC, and HC subjects. CD8 <sup>+</sup> TEM were
160	significantly activated by various S, N, and M peptide pools in CC subjects while remaining
161	relatively quiescent after antigen stimulation in CN patients (Fig. 4A-B). CD8 <sup>+</sup> TEMRA are
162	terminally differentiated memory cells with distinct transcriptional programs that respond
163	quickly to viral infections (Tian et al., 2019). Total percentages of CD8 <sup>+</sup> TEMRA cells were
164	significantly elevated in CN compared with CC and HC groups (Fig. 4C), but despite their
165	increased numbers, $CD8^+$ TEMRA cells were less activated by the S3/4 peptide pool in CN

patients and showed a trend towards decreased activation after N pool stimulation compared withCC subjects (Fig. 4D-E).

168 Similarly, antigen stimulation resulted in altered cytokine polarization in CD8<sup>+</sup> T cell 169 subsets in CN and CC groups. Effector molecule production in CD8<sup>+</sup> T cells was similar across groups in the unstimulated condition, despite showing some statistically significant differences in 170 171 perforin production (Fig. S6B). However, stimulation with the S3/4 pool induced greater TNF- $\alpha$ 172 production in the CC group while CN patients had enhanced IL-6 production to the same 173 stimulus (Fig. 4F). S pool stimulation also induced CD8<sup>+</sup> TEMRA cells from the CC group to 174 produce elevated levels of granzymes, which was not seen in CN or HC groups (Fig. 4G, black lines), demonstrating that CD8<sup>+</sup> T cell subsets display decreased functionality in CN vs. CC 175 patients after stimulation. 176

177 Impaired cognition and decreased quality of life metrics correlate with distinct patterns of
178 polyfunctionality in memory T cell subsets

179 Having shown that Tfh and T cell memory responses differed between patient groups, we next sought to probe whether within-group differences in T cell responses correlated with 180 various clinical measures in CN patients. We found a significant positive correlation between the 181 magnitude of IFN-y production to N protein and higher pain interference scores (Fig. 5A). There 182 183 was also a trend towards a positive correlation between high scores for depression and the 184 magnitude of the N-specific T cell response (Fig. 5B). To look at associations between clinical parameters and T cell activation, we separated T scores from NIH Toolbox or PROMIS-57 185 measurements (Fig. 1C-D) into quartiles and only the lowest and highest groups (Q1 vs. Q4) 186 187 were used for analysis (Fig. S7A, red boxes). CN subjects reporting high (O4) pain interference scores produced significantly less granzyme A or B and more IL-6 than those with low scores 188

189	(Fig. 5C-D) from CD8 <sup>+</sup> T cells after S pool stimulation. Further, patients reporting low
190	depression scores had highly polyfunctional Spike-specific CD8 <sup>+</sup> TEM, while those reporting
191	high levels of depression had TEM producing ~3-fold higher granzymes A, B, and M alone
192	(category 2; Fig. 5E, F). The severity of cognitive impairment could also be significantly
193	correlated with T cell responses. Q1 patients scoring low on executive function tests had $\text{CD8}^+$
194	TCM polarized towards granzymes A, B, M and perforin production (category 1), while those in
195	Q4 were biased to produce granzymes A, B, and perforin (Fig. 5G-H). Similar analyses were
196	performed for other CD8 <sup>+</sup> and CD4 <sup>+</sup> memory T cell subsets, and significant differences by
197	quartile were also found in correlations with depression, processing speed, working memory, and
198	global pain (Fig. S7B-K). These data show that the severity of cognitive deficits or quality of life
199	measures can be significantly correlated with differences in SARS-CoV-2-specific memory T
200	cell function.

SARS-CoV-2 vaccination induces sustained elevation in Spike-specific IFN-y responses in neuro PASC but not healthy COVID convalescents

SARS-CoV-2 mRNA vaccines have been proven to be highly effective against 203 contracting infection in the short-term in both clinical trials and in real-world settings (Haas et 204 205 al., 2021; Polack et al., 2020). However, neither clinical trials nor field studies specifically characterized the vaccine-induced immune response in long-COVID patients, and it is similarly 206 unknown whether vaccination can ameliorate long-haul symptoms. One prospective study 207 showed that vaccination did not significantly worsen symptoms in 22 patients with long-COVID 208 (Arnold et al., 2021), but also did not provide evidence to show any decrease in symptoms. To 209 address how vaccine-induced immunity evolves over time in neuro-PASC long-haulers, we 210 conducted a longitudinal vaccine study assessing Spike-specific antibody and T cell responses 211

212 over the course of 6 months post-vaccination (study design and patient demographics in Fig. 6A-B). While this study is ongoing, we report data from the first 4 months comparing responses in 213 CN, CC, and HC subjects (n for each group per study visit shown in Fig. S8). Vaccination with 214 215 either Pfizer or Moderna mRNA vaccines induced robust SARS-CoV-2 Spike RBD IgG titers in all groups tested by 3 weeks post-2<sup>nd</sup> dose, with the highest titers found in CN patients. Antibody 216 titers were at similar levels in all groups by 3 months post-1<sup>st</sup> dose, but trended higher in CN than 217 in HC subjects at visit (V)4 (Fig. 6C). In parallel, we measured Spike-specific T cell responses in 218 study subjects. The magnitude and kinetics of the T cell response in CC and HC subjects were 219 220 similar and peaked at V3. However, CN patients had significantly elevated Spike-specific T cell responses compared with either HC or CC groups at V2 after the vaccination boost (Fig. 6D; 221 individual pool data shown in Fig. S9). IFN-γ-specific T cell responses remained high at 4 222 223 months post-vaccination in CN patients while not significantly differing from pre-vaccination levels in both CC and HC subjects. To our knowledge, these are the first data that longitudinally 224 compare the T cell response to vaccination in neuro-PASC patients with healthy COVID 225 convalescents and unexposed individuals. 226

Overall, our study demonstrates that neuro-PASC patients have elevated IFN-y responses 227 to N and M proteins, enhanced Ag-specific activation of Tfh cells, sustained anti-N IgG 228 229 production, and deficient activation of multiple CD8<sup>+</sup> memory T cell subsets compared with healthy COVID-19 convalescents. There were also correlations between the severity of cognitive 230 deficits or quality of life impairments and Ag-specific cytokine signatures (Fig. 5, S7). 231 Importantly, vaccination resulted in sustained enhancements in the magnitude of Spike-specific 232 T cell responses in neuro-PASC patients vs. all other groups, regardless of prior COVID 233 234 exposure. Together, we show that CN patients exhibit a large-scale dysfunction in multiple

- aspects of the memory T cell response which may inform treatment and/or vaccination options
- down the line.

#### 237 Discussion

238	COVID-19 is well-recognized as a multi-organ disease with long-term sequelae
239	associated with neurological disease. PASC has been reported in up to 87% of those hospitalized
240	with SARS-CoV-2 pneumonia and in up to 40% of those with mild disease who do not require
241	hospitalization (Havervall et al., 2021; Hirschtick et al., 2021; Mahase, 2020). SARS-CoV-2
242	vaccines have decreased the rates of SARS-CoV-2 infection and mortality in unexposed
243	individuals, but it is not clear that vaccines help to ameliorate long-COVID symptoms in
244	previously infected individuals (Arnold et al., 2021) and thus further study is needed to inform
245	treatment options. Long-term sequelae after other coronavirus infections can persist for years
246	(Ahmed et al., 2020); therefore, it is important to specifically characterize SARS-CoV-2-specific
247	immune responses in long-COVID patients. Most studies on effector and memory T cell
248	responses to SARS-CoV-2 have focused on acute infection or healthy convalescents as opposed
249	to those with long-COVID (Rodda et al., 2021; Sekine et al., 2020; Weiskopf et al., 2020). We
250	aimed to fill this knowledge gap and determine whether and how T cell phenotype and function
251	differ in patients with neuro-PASC and healthy COVID-19 convalescents.

Clinically, neuro-PASC resembles myalgic encephalomyelitis/chronic fatigue syndrome 252 253 (ME/CFS), which many patients report as a post-viral infectious complication (Rasa et al., 2018). 254 The causes of ME/CFS remain elusive, and the underlying mechanisms of neuro-PASC remain similarly unknown. It is possible that direct infection of the brain is responsible for neuro-PASC 255 256 symptoms. It is believed that SARS-CoV-2 gains entry into the central nervous system through the olfactory bulb and has been shown to infect neurons in vitro, which is supported by findings 257 of viral protein expression in cortical neurons from post-mortem autopsies (Klingenstein et al., 258 2020; Song et al., 2021). However, another study was unable to find any evidence of SARS-259

260	CoV-2 in the brains of 4 patients with neurological symptoms during acute infection (Kantonen
261	et al., 2020), suggesting that infection of the nervous system may be transient. Another study of
262	acutely infected neuro-COVID patients did not find any SARS-CoV-2 RNA present in the CSF,
263	though they did identify enhanced presence of exhausted T cells and dedifferentiated monocytes
264	(Heming et al., 2021). However, all of these prior studies were conducted on patients with acute
265	SARS-CoV-2 infection as opposed to neuro-PASC, and thus mechanisms for neurological
266	dysfunction may differ. As lumbar punctures or brain biopsies are not indicated in neuro-PASC
267	outpatients, reproducing the above study results in outpatient populations will not be possible.
268	Additional hypotheses for neuro-PASC pathogenesis include a contribution of autoimmune
269	mechanisms which is suggested by the skewed ratio of females to males affected, similar to that
270	seen in rheumatoid arthritis or systemic lupus erythematosus (Chakravarty et al., 2007;
271	Myasoedova et al., 2010), as well as the possibility of persistent SARS-CoV-2 infection in the
272	periphery (Al-Aly et al., 2021). Much of our findings on the SARS-CoV-2 T cell response in
273	neuro-PASC patients supports this latter hypothesis.
274	Ag-specific IFN- $\gamma$ and IL-2 production was similar between CN and CC groups in
275	response to stimulation by different SARS-CoV-2 Spike peptide pools (Fig. 2A-B). However, T
276	cells from CN patients retained high IFN-y responses to all N- and M-peptide pools tested, while
277	CC subjects had a reactivity limited to N1 and N2 peptide pools with little IFN- $\gamma$ production in
278	response to M pools (Fig. 2C-D). The presence of an immunodominance hierarchy in CC
279	subjects is the expected outcome of an effective memory response to SARS-CoV-2 infection.
280	Studies have shown that while a primary CD4 <sup>+</sup> or CD8 <sup>+</sup> T cell response to influenza A or LCMV
281	infection is highly diverse and contains T cells reactive to many viral proteins and epitopes, the
282	memory response preferentially contains T cells responding to specific immunodominant viral

283	antigens (Sant et al., 2018; Tebo et al., 2005). This effect is more pronounced in the CD8 <sup>+</sup> T cell
284	compartment where memory responses are dependent on the ability of dendritic cells to present
285	viral antigen (Crowe et al., 2003) or on antigen availability (Henrickson et al., 2013). The
286	evident lack of a narrow and targeted IFN-7 response to N- and M-peptides in CN patients thus
287	suggests that they are unable to effectively generate a memory response to SARS-CoV-2.
288	Though there were no differences observed in the magnitude or specificity of the IFN- $\gamma$ response
289	to SARS-CoV-2 Spike peptides, this is somewhat expected as memory T cell responses to Spike
290	protein remain diverse after both infection (Grifoni et al., 2020) and vaccination (Alter et al.,
291	2021). It is additionally not surprising that differences in reactivity were observed for IFN- $\gamma$ and
292	not IL-2 T cell responses between CN and CC groups (Fig. 2B, E-F). Studies have demonstrated
293	that while Ag-specific T cells produce IL-2 as a proliferation factor, IFN- $\gamma$ production is largely
294	confined to the memory T cell population (Anthony et al., 2012), which is largely where we see
295	differences in activation and reactivity between groups (Fig. 4).
296	Antibody production is a key outcome measure after SARS-CoV-2 infection, Tfh cell
297	activation can inform the effectiveness of an antibody response. Stimulation with SARS-CoV-2
298	N peptides activated Tfh cells in CN but not CC subjects, while the opposite trend was found
299	with M pool stimulation (Fig. 3A-B). Tfh cell activation is crucial to the establishment of
300	germinal centers in secondary lymphoid organs, ultimately resulting in B cell maturation into
301	long-lived plasma cells that can continuously produce class-switched, high-affinity antibodies
302	(Good-Jacobson and Shlomchik, 2010). Studies have demonstrated that the magnitude of the Tfh
303	cell response is dependent on the amount of antigen available and directly correlates with the

magnitude of the B cell response (Baumjohann et al., 2013). Indeed, the same CN patients with

305 high N-specific Tfh cell activation also displayed anti-N IgG titers significantly greater than CC

306	subjects (Fig. 3E) despite the fact that we obtained their samples more than 6 months on average
307	after acute infection. Altogether, these findings are consistent with the presence of a persisting
308	nucleocapsid antigen reservoir resulting in enhanced N-specific Tfh cell activation in CN
309	patients. Clinical reports have identified cases of persistent SARS-CoV-2 infection in the
310	nasopharynx lasting up to 63 days (Bennasrallah et al., 2020) and many patients re-tested RT-
311	PCR+ for SARS-CoV-2 up to 38 days post-discharge (Dao et al., 2021). Though many of our
312	CN patients have not re-tested RT-PCR+ by nasal swab (data not shown), others have yet to be
313	tested. The nasopharynx is not the only possible testing site, however, as there are numerous
314	studies showing that infectious SARS-CoV-2 particles can be detected in fecal matter and can
315	persist for up to 70 days post-symptom onset (Tian et al., 2020; van Doorn et al., 2020).
316	Gastrointestinal symptoms also did not have to be present in order to test RT-PCR+ for SARS-
317	CoV-2 in stool samples (Chen et al., 2020). Thus, it is possible that the gut may also act as a
318	reservoir for persistent SARS-CoV-2 infection which leads to aberrant T cell responses and the
319	development of neuro-PASC.
320	Effective generation of T cell memory responses is crucial to protect against future
321	infections with the same pathogen. CD8 <sup>+</sup> TEM cells from CC subjects retained high levels of
322	activation to all S, N, and M pools assayed while CN patients displayed very little TEM
323	activation (Fig. 4A-B), suggestive of aberrant memory T cell function. Studies on convalescents
324	from the original SARS-CoV epidemic of 2002-03 found that the majority of Ag-specific CD8 <sup>+</sup>

memory T cells were TEM, and these persisted up to 4 years after infection (Channappanavar et

al., 2014). Sterilizing immunity can be a precondition for the development and maintenance of

327 memory T cells because high levels of foreign antigen favor the generation of short-lived

328 effector cells (Mueller et al., 2013), which is why chronic infections often limit the formation

329	and/or function of memory T cells (Wherry, 2011). In fact, chronic LCMV infection in mice
330	induced aberrantly functioning Ag-specific memory CD8 <sup>+</sup> T cells requiring the presence of viral
331	peptide rather than simply the homeostatic cytokines IL-7 and IL-15 to proliferate (Shin et al.,
332	2007; Wherry et al., 2004). The inability of CD8 <sup>+</sup> TEM to become activated by antigenic
333	stimulation in CN patients is thus suggestive of a chronic infection state wherein viral antigen
334	can persist but limits the formation of CD8 <sup>+</sup> T cell memory. It is also possible that chronic
335	SARS-CoV-2 infection in CN patients leads to memory T cell exhaustion, as shown in chronic
336	HIV and HBV infections in humans (McLane et al., 2019). However, we did not find any
337	differences in the inhibitory marker PD-1 expression on CD8 <sup>+</sup> memory T cell subsets between
338	CN and CC patients (data not shown).
339	Further providing support to the chronic infection hypothesis in neuro-PASC patients,
340	there was a significant elevation in the CD8 <sup>+</sup> TEMRA cell population in CN patients over CC or
341	HC groups (Fig. 4C). CD8 <sup>+</sup> TEMRA cells are a terminally differentiated memory subset that do
342	not traffic through secondary lymphoid organs, and their induction during viral infection can be
343	protective (Tian et al., 2019). Yet, they have also been shown to accumulate during persistent
344	viral infections and contribute to immunosenescence (Derhovanessian et al., 2011). CD8 <sup>+</sup>
345	TEMRA cell reactivity to SARS-CoV-2 peptides was also decreased in CN patients over CC
346	subjects. Functionally, the polarization in granzyme production in S3/4-specific CD8 <sup>+</sup> TEMRA
347	cells from CC patients (Fig. 4G) suggests higher cytotoxic capacity compared with CN patients
348	and coincides with their higher activation state in Fig. 4E. Ag-specific CD8 <sup>+</sup> TEMRA cells are
349	expanded and functionally active in people with significant anti-Dengue virus immunity, and this
350	phenotype is seen as a goal for vaccine-induced protection (Tian et al., 2019). We propose that
351	CD8 <sup>+</sup> TEMRA cells are more expanded but less functionally active in CN subjects over CC as a

consequence of inappropriate CD8<sup>+</sup> T cell memory formation, which is lacking in multiple T cell
subsets for neuro-PASC patients.

354 We also showed that  $CD8^+$  T cells from CC subjects skewed towards TNF- $\alpha$  production 355 after S pool stimulation compared with CN patients. Comparatively, CN patients displayed 356 significantly more IL-6 production from S-specific CD8<sup>+</sup> T cells (Fig. 4F). Vaccination against 357 the intracellular pathogen *Shigella flexneri* showed that polyfunctional TNF- $\alpha$ -producing CD8<sup>+</sup> 358 TEM were an important correlate of protection (Toapanta et al., 2018). Despite multiple reports 359 indicating that enhanced TNF-a production is correlated with worse COVID-19 outcomes (Karki 360 et al., 2020, 2021; Pedersen and Ho, 2020), we speculate that Ag-specific TNF-α production is protective in our model system because we are looking at chronically and not acutely infected 361 CN patients. In contrast, IL-6 is known to suppress T<sub>H</sub>1 differentiation (Diehl et al., 2000) and 362 363 can promote pathogen survival and exacerbate clinical disease during the original SARS-CoV infection (Channappanavar and Perlman, 2017). Indeed, studies in severely ill, hospitalized 364 COVID-19 patients demonstrated that high serum levels of IL-6 significantly correlated with 365 poor clinical outcome (Weiskopf et al., 2020). These data suggest a role for enhanced IL-6 366 367 production by CD8<sup>+</sup> T cells in the pathogenesis of neuro-PASC, and open new avenues of research for the treatment of long-COVID through limiting IL-6 activity. 368

Clinically, neuro-PASC patients reported significantly elevated levels of anxiety, depression, fatigue, sleep disturbance and pain as well as decreased physical function compared with healthy convalescents (Fig. 1C). The severity of these deficits was highly correlated with Ag-specific enhancements in polyfunctionality and decreases in polarization of various memory T cell subsets (Fig. 5, S7). It is possible that T cell function contributes to the genesis and persistence of some of these symptoms. Studies in rodents have shown that T cell activation and

375 function can affect the severity of pain and analgesia (Rosen et al., 2019; Sorge et al., 2015). Indeed, pain is a common hallmark of chronic viral infection (Addis et al., 2020) and recognized 376 among post-COVID sequelae (Kemp et al., 2020); it might follow then that aberrant T cell 377 378 activation can associate with high pain scores. Additionally, reports have shown that transcriptional programs in immunity and inflammation were differentially regulated in CD4<sup>+</sup> T 379 cells from patients with depression compared with healthy controls (Wang et al., 2015). T<sub>reg</sub> cells 380 may also decrease depressive behavior through negative regulation of inflammation (Miller, 381 2010), and CN patients do display elevated  $T_{\rm H}$ 1-type cytokine production to S pool stimulation 382 (Fig. 2, 6) while not displaying any compensatory upregulation in T<sub>reg</sub> total numbers or function 383 (data not shown). T cell-derived cytokines can also impact learning and memory. Studies in 384 mouse models of West Nile and Zika viral encephalitis have demonstrated that IFN-y production 385 from CD8<sup>+</sup> T cells in the brain is responsible for neuronal apoptosis and spatial learning deficits 386 (Garber et al., 2019). Thus, there is a precedent for correlating T cell function with cognitive 387 deficits, pain, or depression. Ag-specific cytokine signatures associated with the severity of 388 cognitive and quality of life deficits in neuro-PASC patients may therefore provide some 389 predictive value in terms of clinical outcomes. 390

Preliminary reports showed that the Pfizer mRNA vaccine could elicit a T cell response 7 days after completion of the full prime-boost protocol (Sahin et al., 2020), but until our studies there has been no data on longitudinal T cell responses primed by vaccination and how these vary between groups with different types of prior SARS-CoV-2 exposure. Our results demonstrate for the first time that vaccine-elicited immune responses are significantly divergent in neuro-PASC versus healthy COVID convalescents (Fig. 6C-D). CN patients consistently had higher antibody titers after receiving the second dose of the vaccine compared with CC and HC

398 groups, though titers were similar in all groups at 11-15 weeks post-1<sup>st</sup> dose (Fig. 6C). In contrast, the magnitude of Spike-specific IFN-y production by T cells remained high in CN 399 patients out to 4 months post-vaccination while not significantly higher than pre-vaccination 400 levels in CC and HC subjects along the same timeline (Fig. 6D). These data suggest that the 401 mRNA vaccines do not induce robust long-term T cell responses in many individuals, regardless 402 of prior COVID exposure, if they are not neuro-PASC patients. Yet, despite vaccines enhancing 403 Spike-specific IFN-y production in CN T cells, the fact that these responses continue to increase 404 at 15 weeks post-vaccination suggests that CN patients may still have an active SARS-CoV-2 405 406 infection or a persistent antigen reservoir rather than developing a robust T cell memory response. These results suggest that alternate SARS-CoV-2 vaccines that induce long-lasting 407 memory T cell responses in previously unexposed individuals as well as healthy COVID 408 convalescents are needed in order to mediate long-term protection from infection. Conversely, 409 vaccination may not be indicated for long-COVID patients who might have a persistent infection 410 as it may be ineffective in the absence of viral clearance. Indeed, current clinical guidance from 411 the CDC recommends that vaccination be delayed until 3 months after acute infection in 412 unvaccinated COVID convalescents. Thus, vaccination strategies that include the memory T cell 413 414 response as a marker for efficacy should be carefully considered. Together, these data show that irregular Tfh responses, broad scale dysfunction in CD8<sup>+</sup> T cell memory generation and aberrant 415 T cell responses to vaccination are hallmarks of neuro-PASC and require further study to inform 416 417 treatment and vaccination strategies across the population.

#### 418 Limitations of study

One limitation of our study is the relatively small sample size of unvaccinated neuroPASC patients. This was due to the wide implementation of SARS-CoV-2 vaccines in the

- 421 Chicago area soon after beginning study enrollment. Another limitation was not being able to
- 422 control for time of sample collection with respect to date of COVID-19 symptom onset. As it is
- 423 possible that neuro-PASC could be the result of a persistent infection, further investigations
- 424 would require testing of potential cryptic reservoirs, including stool samples from CN patients.

#### 426 Materials and Methods

#### 427 *Ethics Statement*

- 428 This study was approved by the Northwestern University Institutional Review Board (Koralnik
- 429 Lab, IRB STU00212583). Informed consent was obtained from all enrolled participants. Samples
- 430 were de-identified before banking.
- 431 Study participants, NIH Toolbox, and PROMIS-57 data collection

We enrolled consenting unvaccinated adult outpatients seen in the Neuro-PASC-19 clinic at 432 433 Northwestern Memorial Hospital from September 2020-June 2021, including 56 neuro-PASC "long-hauler" patients with documented PCR+ or seropositive IgG results for SARS-CoV-2 434 (CN). In parallel, we recruited 24 unvaccinated healthy COVID convalescents from the 435 436 surrounding community who tested PCR+ for SARS-CoV-2 but had no lingering neurological symptoms (CC) and 31 healthy controls who tested PCR- for SARS-CoV-2 and were also 437 seronegative for IgG against SARS-CoV-2 Spike RBD. All study subjects remained living 438 throughout the period of observation. Heparinized blood samples were collected one time from 439 each subject at an average of 155-315 days post-symptom onset (as in Fig. 1B). Other 440 441 demographic information is contained in Fig. 1B. CN patients completed a cognitive function 442 evaluation in the clinic coincident or near the date of their blood sample acquisition with the National Institutes of Health (NIH) Toolbox v2.1 instrument, including assessments of: 443 444 processing speed (pattern comparison processing speed test); attention and executive memory (inhibitory control and attention test); executive function (dimensional change card sort test); and 445 working memory (list sorting working memory test) (Lai et al., 2011; Weintraub et al., 2013). 446 PROMIS-57 was administered to CN and CC patients an average of 72 days post-sample 447

448	collection. Both PROMIS-57 and NIH Toolbox results are expressed as T-scores adjusted for			
449	age, education, gender, and race/ethnicity with a score of 50 representing the normative			
450	mean/median of the US reference population with a standard deviation of 10. Lower cognition T-			
451	scores indicate worse performance while higher fatigue, depression, anxiety, or pain interference			
452	T-scores indicate greater symptom severity.			
453	PBMC and plasma collection			
454	30mL of venous blood from study volunteers was collected in blood collection tubes containing			
455	sodium heparin from BD Biosciences. Whole blood was layered on top of 15mL of Histopaque			
456	1077 (Sigma-Aldrich) in 50mL Leucosep blood separation tubes (Greiner Bio-One) and spun at			
457	1000g for 18min at RT. Plasma was collected and stored at -80°C. The PBMC layer was			
458	collected and washed 2x in sterile PBS before red blood cell lysis with ACK buffer (Quality			
459	Biologicals). PBMCs were used in assays either immediately or frozen down for use in the near			
460	term.			

#### 461 *SARS-CoV-2 peptide antigens*

462 All S, N and M peptide arrays used in ELISPOT and flow cytometry studies were obtained from

463 BEI Resources, NIAID, NIH: Peptide Array, SARS-Related Coronavirus 2 Spike (S) Protein;

464 NR-52402, Nucleocapsid (N) Protein, NR-52404; Membrane (M) Protein, NR-52403. The S

465 peptide array consisted of 181 peptides of 13-17aa in length and split into 6 sub-pools (S1-S6)

466 containing 30-31 peptides each. The N peptide array consisted of 59 peptides of 13-17aa each

- split into 3 sub-pools containing 29-30 peptides each. The M peptide array consisted of 31
- 468 peptides of 12-17aa and split into 3 sub-pools of 10-11 peptides each (Fig. S1). All peptides were

dissolved in either sterile H<sub>2</sub>O or 50% sterile H<sub>2</sub>O-DMSO up to 1mL for a universal 1mg/mL
stock concentration. Peptides were used at a final concentration at 2µg/mL in all assays.

#### 471 IgG Spike RBD and Nucleocapsid ELISA

Antigen-specific total antibody titers were measured by ELISA as described previously (Dangi et al., 2020; Palacio et al., 2020). In brief, 96-well flat-bottom MaxiSorp plates (Thermo Scientific) were coated with 1  $\mu$ g/ml of Spike RBD for 48 hr at 4°C. Plates were washed three times with wash buffer (PBS + 0.05% Tween 20). Blocking was performed with blocking solution (PBS + 0.05% Tween 20 + 2% bovine serum albumin), for 4 hr at room temperature. 6  $\mu$ l of sera was added to 144  $\mu$ l of blocking solution in the first column of the plate, 1:3 serial dilutions were performed until row 12 for each sample, and plates were incubated for 60 min at room

temperature. Plates were washed three times with wash buffer followed by addition of secondary

480 antibody conjugated to horseradish peroxidase, goat anti-human IgG (H + L) (Jackson

481 ImmunoResearch) diluted in blocking solution (1:1000) and 100 µl/well was added and

482 incubated for 60 min at room temperature. After washing plates three times with wash buffer,

483 100 μl/well of Sure Blue substrate (SeraCare) was added for 1 min. Reaction was stopped using

484 100 μl/well of KPL TMB Stop Solution (SeraCare). Absorbance was measured at 450 nm using

485 a Spectramax Plus 384 (Molecular Devices). SARS-CoV-2 RBD and N proteins used for ELISA

486 were produced at the Northwestern Recombinant Protein Production Core by Dr. Sergii

487 Pshenychnyi using plasmids that were produced under HHSN272201400008C and obtained from

488 BEI Resources, NIAID, NIH: Vector pCAGGS containing the SARS-related coronavirus 2,

489 Wuhan-Hu-1 spike glycoprotein gene (soluble, stabilized), NR-52394 and receptor binding

domain (RBD), NR-52309, nucleocapsid gene NR-53507.

491 *Cell stimulation and IFN-y/IL-2 ELISPOT* 

492	Multiscreen-IP plates (Millipore-Sigma) were coated overnight at 4°C with $2\mu g/mL$ anti-IFN- $\gamma$				
493	(clone 1-D1K, Mabtech) or 5µg/mL anti-IL-2 (clone MT2A91/2C95, Mabtech), washed with				
494	sterile PBS, and blocked with complete RPMI-10% FBS. PBMC isolated from CN, CC, and H				
495	subjects were used either freshly isolated or after thawing and resting overnight in media				
496	containing 10ng/ $\mu$ L recombinant human IL-15 (Peprotech) at 37°C, 5% CO <sub>2</sub> . Cells were then				
497	plated at a concentration of $2.5 \times 10^5$ cells/well in $100 \mu L$ of media and stimulated with the				
498	indicated antigen mixtures from SARS-CoV-2 at a concentration of 2µg/mL in complete RPMI				
499	medium containing 5% human AB serum (Sigma-Aldrich) and 5ng/mL IL-15. Plates were				
500	incubated at 37°C, 5% CO <sub>2</sub> for 20 h and washed 5x with dH <sub>2</sub> O and PBS-0.05% Tween-20 (PBS-				
501	T). 2µg/mL biotinylated IFN-γ (clone 7-B6-1, Mabtech) or 5µg/mL IL-2 (clone MT8G10,				
502	Mabtech) diluted in PBS-10% FBS (PBS-F) was added to the respective wells and plates were				
503	incubated for 1.5h at RT. Plates were subsequently incubated for 40 minutes at RT in				
504	streptavidin-alkaline phosphatase in PBS-F (Jackson ImmunoResearch) was added after washing				
505	plates 5x in PBS-T. ELISPOT plates were developed using an Alkaline Phosphatase Conjugate				
506	Substrate Kit according to manufacturer's instructions (Bio-Rad Laboratories, Carlsbad, CA).				
507	IFN-γ or IL-2-producing cells were quantified using an ImmunoSpot reader (Cellular				
508	Technologies, Ltd., Shaker Heights, OH).				
509	Antibodies and Flow Cytometry				

510 Fresh or frozen PBMCs isolated from the indicated patient groups were stimulated with antigen

511 mixtures as above for 20-22h at 37°C, 5% CO<sub>2</sub>. For intracellular staining and cytokine detection,

- the Brefeldin-A Golgi plug (Biolegend) was added at a 1:1000 concentration 2 hours after
- antigenic stimulation commenced. Cells were washed with PBS-1% BSA after incubation and
- 514 incubated with the indicated antibodies for surface phenotyping by AIM assay or for intracellular

515	cytokine staining (ICS). Cells from each subject were left unstimulated in medium containing
516	5ng/mL IL-15 ("background") or stimulated in the presence of the indicated antigens. Fixation
517	and permeabilization was performed using Cytofix/Cytoperm (BD Biosciences). Surface staining
518	was done in the dark at 4°C for 30 minutes, while ICS was done in the dark at RT for 45
519	minutes. Flow cytometry was conducted on $2-5 \times 10^5$ cells per condition. Data was acquired on a
520	BD FACSymphony Spectral analyzer and analyzed using FlowJo v10 (BD Biosciences) and

521 SPICE-Pestle (Roederer et al., 2011).

#### 522 Quantification and Statistical Analysis

523 Statistical tests to determine significance are described in figure legends and conducted largely in Prism (GraphPad). For pie graphs or heatmaps generated using SPICE analysis, statistics were 524 determined by Permutation test following unstimulated background subtraction, with additional 525 thresholding of 0.03% to account for noise, using SPICE-Pestle. P-values lower than 0.05 were 526 considered statistically significant. Quantile stratification was performed within group for CN 527 528 cohort. Clinical data were collected and managed using REDCap electronic data capture tools 529 hosted at Northwestern University Feinberg School of Medicine (Harris et al., 2009). REDCap (Research Electronic Data Capture) is a secure, web-based software platform designed to support 530 531 data capture for research studies, providing 1) an intuitive interface for validated data capture; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures 532 for seamless data downloads to common statistical packages; and 4) procedures for data 533 integration and interoperability with external sources. 534

535

536

# 537 Acknowledgements

538	We would like to thank the Flow Cytometry Core Facility at the Robert H. Lurie Comprehensive			
539	Cancer Center at Northwestern University supported by Cancer Center Support Grant (NCI			
540	CA060553) for their assistance in optimizing antibody panels and help with flow cytometry			
541	instrumentation. L.V. was supported by a T32 grant T32AR007611 from the Department of			
542	Rheumatology, Northwestern University Feinberg School of Medicine. P.P.M. is supported by a			
543	grant from the Emerging and Re-Emerging Pathogens Program (EREPP) at Northwestern			
544	University, and a grant from the National Institute on Drug Abuse (NIDA, DP2DA051912).			
545				
546	Author Contributions			
547	Conceptualization L.V. P.P.M. and I.K; Investigation L.V., B.H., Z.O., P.H.L, and N.P.; Formal			
548	Analysis L.V., B.H., E.M.L., P.P.M. and N.P.; Resources L.V., P.P.M., I.K., Data Curation L.V.;			
549	Writing L.V. with feedback from all authors; Supervision P.P.M and I.K.; Project Administration			
550	L.V.; Funding Acquisition L.V., P.P.M, and I.K.			
551				
552	Declaration of Interests			
553	The authors declare no competing interests.			
554				
555				
556				

#### 557 **References**

- Addis, D.R., DeBerry, J.J., and Aggarwal, S. (2020). Chronic Pain in HIV. Mol Pain 16,
- 559 1744806920927276.
- 560 Ahmed, H., Patel, K., Greenwood, D.C., Halpin, S., Lewthwaite, P., Salawu, A., Eyre, L., Breen,
- A., O'Connor, R., Jones, A., et al. (2020). Long-term clinical outcomes in survivors of severe
- acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after
- hospitalisation or ICU admission: A systematic review and meta-analysis. J Rehabil Med 52,
- 564 jrm00063.
- Al-Aly, Z., Xie, Y., and Bowe, B. (2021). High-dimensional characterization of post-acute
- sequelae of COVID-19. Nature *594*, 259-264.
- 567 Alter, G., Yu, J., Liu, J., Chandrashekar, A., Borducchi, E.N., Tostanoski, L.H., McMahan, K.,
- Jacob-Dolan, C., Martinez, D.R., Chang, A., et al. (2021). Immunogenicity of Ad26.COV2.S
- 569 vaccine against SARS-CoV-2 variants in humans. Nature.
- 570 Anthony, D.D., Milkovich, K.A., Zhang, W., Rodriguez, B., Yonkers, N.L., Tary-Lehmann, M.,
- and Lehmann, P.V. (2012). Dissecting the T Cell Response: Proliferation Assays vs. Cytokine
- 572 Signatures by ELISPOT. Cells 1, 127-140.
- Arnold, D.T., Milne, A., Samms, E., Stadon, L., Maskell, N.A., and Hamilton, F.W. (2021).
- 574 Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute
- 575 Infection: A Case Series. Ann Intern Med.
- 576 Baumjohann, D., Preite, S., Reboldi, A., Ronchi, F., Ansel, K.M., Lanzavecchia, A., and
- 577 Sallusto, F. (2013). Persistent antigen and germinal center B cells sustain T follicular helper cell
- responses and phenotype. Immunity *38*, 596-605.

- 579 Bennasrallah, C., Bannour, R., Jlassi, O., Kacem, M., Fredj, M.B., Abroug, H., Zemni, I.,
- 580 Garrach, B., Bahri, R., Charfeddine, N., et al. (2020). Three COVID-19 cases with a long-term
- viral shedding period in Tunisia. Pan Afr Med J *35*, 117.
- 582 Center, J.C.R. (2021). Cumulative worldwide Covid-19 cases (Baltimore, MD: Johns Hopkins
- 583 University of Medicine).
- 584 Chakravarty, E.F., Bush, T.M., Manzi, S., Clarke, A.E., and Ward, M.M. (2007). Prevalence of
- adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained
- using hospitalization data. Arthritis Rheum 56, 2092-2094.
- 587 Channappanavar, R., and Perlman, S. (2017). Pathogenic human coronavirus infections: causes
- and consequences of cytokine storm and immunopathology. Semin Immunopathol 39, 529-539.
- 589 Channappanavar, R., Zhao, J., and Perlman, S. (2014). T cell-mediated immune response to
- respiratory coronaviruses. Immunol Res 59, 118-128.
- 591 Chen, H., Hou, J., Jiang, X., Ma, S., Meng, M., Wang, B., Zhang, M., Zhang, M., Tang, X.,
- 592 Zhang, F., et al. (2005). Response of memory CD8+ T cells to severe acute respiratory syndrome
- (SARS) coronavirus in recovered SARS patients and healthy individuals. J Immunol *175*, 591598.
- 595 Chen, Y., Chen, L., Deng, Q., Zhang, G., Wu, K., Ni, L., Yang, Y., Liu, B., Wang, W., Wei, C.,
- *et al.* (2020). The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. J Med
  Virol *92*, 833-840.
- 598 Crowe, S.R., Turner, S.J., Miller, S.C., Roberts, A.D., Rappolo, R.A., Doherty, P.C., Ely, K.H.,
- and Woodland, D.L. (2003). Differential antigen presentation regulates the changing patterns of
- 600 CD8+ T cell immunodominance in primary and secondary influenza virus infections. J Exp Med
  601 *198*, 399-410.

- Dao, T.L., Hoang, V.T., and Gautret, P. (2021). Recurrence of SARS-CoV-2 viral RNA in
- recovered COVID-19 patients: a narrative review. Eur J Clin Microbiol Infect Dis 40, 13-25.
- 604 Derhovanessian, E., Maier, A.B., Hahnel, K., Beck, R., de Craen, A.J.M., Slagboom, E.P.,
- 605 Westendorp, R.G.J., and Pawelec, G. (2011). Infection with cytomegalovirus but not herpes
- simplex virus induces the accumulation of late-differentiated CD4+ and CD8+ T-cells in
- 607 humans. J Gen Virol 92, 2746-2756.
- Diehl, S., Anguita, J., Hoffmeyer, A., Zapton, T., Ihle, J.N., Fikrig, E., and Rincon, M. (2000).
- Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1. Immunity 13, 805-815.
- 610 Duan, Y.Q., Xia, M.H., Ren, L., Zhang, Y.F., Ao, Q.L., Xu, S.P., Kuang, D., Liu, Q., Yan, B.,
- EXAMPLE 21 Shou, Y.W., et al. (2020). Deficiency of Tfh Cells and Germinal Center in Deceased COVID-19
- 612 Patients. Curr Med Sci 40, 618-624.
- Garber, C., Soung, A., Vollmer, L.L., Kanmogne, M., Last, A., Brown, J., and Klein, R.S.
- 614 (2019). T cells promote microglia-mediated synaptic elimination and cognitive dysfunction
- during recovery from neuropathogenic flaviviruses. Nat Neurosci 22, 1276-1288.
- 616 Good-Jacobson, K.L., and Shlomchik, M.J. (2010). Plasticity and heterogeneity in the generation
- of memory B cells and long-lived plasma cells: the influence of germinal center interactions and
- 618 dynamics. J Immunol 185, 3117-3125.
- Goubard, A., Loiez, C., Abe, J., Fichel, C., Herwegh, S., Faveeuw, C., Porte, R., Cayet, D.,
- 620 Sebbane, F., Penet, S., et al. (2015). Superantigenic Yersinia pseudotuberculosis induces the
- expression of granzymes and perforin by CD4+ T cells. Infect Immun *83*, 2053-2064.
- Graham, E.L., Clark, J.R., Orban, Z.S., Lim, P.H., Szymanski, A.L., Taylor, C., DiBiase, R.M.,
- Jia, D.T., Balabanov, R., Ho, S.U., et al. (2021). Persistent neurologic symptoms and cognitive
- dysfunction in non-hospitalized Covid-19 "long haulers". Ann Clin Transl Neurol 8, 1073-1085.

- 625 Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R., Rawlings,
- 626 S.A., Sutherland, A., Premkumar, L., Jadi, R.S., et al. (2020). Targets of T Cell Responses to
- 627 SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell
- 628 *181*, 1489-1501 e1415.
- Haas, E.J., Angulo, F.J., McLaughlin, J.M., Anis, E., Singer, S.R., Khan, F., Brooks, N., Smaja,
- 630 M., Mircus, G., Pan, K., et al. (2021). Impact and effectiveness of mRNA BNT162b2 vaccine
- against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a
- nationwide vaccination campaign in Israel: an observational study using national surveillance
- 633 data. Lancet *397*, 1819-1829.
- Halpin, S.J., McIvor, C., Whyatt, G., Adams, A., Harvey, O., McLean, L., Walshaw, C., Kemp,
- 635 S., Corrado, J., Singh, R., *et al.* (2021). Postdischarge symptoms and rehabilitation needs in
- 636 survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol 93, 1013-1022.
- Hampshire, A., Trender W., Chamberlain SR, Jolly AE, Grant JE, Patrick F, Mazibuko N,
- 638 Williams S, Barnaby JM, Hellyer H, Mehta MA. (2021). Cognitive deficits in people who have
- 639 recovered from COVID-19. EClinicalMedicine.
- 640 Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., and Conde, J.G. (2009). Research
- 641 electronic data capture (REDCap)--a metadata-driven methodology and workflow process for
- 642 providing translational research informatics support. J Biomed Inform 42, 377-381.
- Havervall, S., Rosell, A., Phillipson, M., Mangsbo, S.M., Nilsson, P., Hober, S., and Thalin, C.
- 644 (2021). Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19
- 645 Among Health Care Workers. JAMA 325, 2015-2016.
- Heming, M., Li, X., Rauber, S., Mausberg, A.K., Borsch, A.L., Hartlehnert, M., Singhal, A., Lu,
- 647 I.N., Fleischer, M., Szepanowski, F., et al. (2021). Neurological Manifestations of COVID-19

- Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid. Immunity *54*,
  164-175 e166.
- 650 Henrickson, S.E., Perro, M., Loughhead, S.M., Senman, B., Stutte, S., Quigley, M., Alexe, G.,
- Iannacone, M., Flynn, M.P., Omid, S., et al. (2013). Antigen availability determines CD8(+) T
- cell-dendritic cell interaction kinetics and memory fate decisions. Immunity *39*, 496-507.
- Higgins, V., Sohaei, D., Diamandis, E.P., and Prassas, I. (2020). COVID-19: from an acute to
- 654 chronic disease? Potential long-term health consequences. Crit Rev Clin Lab Sci, 1-23.
- Hirschtick, J.L., Titus, A.R., Slocum, E., Power, L.E., Hirschtick, R.E., Elliott, M.R., McKane,
- P., and Fleischer, N.L. (2021). Population-based estimates of post-acute sequelae of SARS-CoV-
- 657 2 infection (PASC) prevalence and characteristics. Clin Infect Dis.
- 658 Kantonen, J., Mahzabin, S., Mayranpaa, M.I., Tynninen, O., Paetau, A., Andersson, N., Sajantila,
- A., Vapalahti, O., Carpen, O., Kekalainen, E., et al. (2020). Neuropathologic features of four
- autopsied COVID-19 patients. Brain Pathol *30*, 1012-1016.
- Karki, R., Sharma, B.R., Tuladhar, S., Williams, E.P., Zalduondo, L., Samir, P., Zheng, M.,
- 662 Sundaram, B., Banoth, B., Malireddi, R.K.S., et al. (2020). COVID-19 cytokines and the
- 663 hyperactive immune response: Synergism of TNF-alpha and IFN-gamma in triggering
- 664 inflammation, tissue damage, and death. bioRxiv.
- 665 Karki, R., Sharma, B.R., Tuladhar, S., Williams, E.P., Zalduondo, L., Samir, P., Zheng, M.,
- 666 Sundaram, B., Banoth, B., Malireddi, R.K.S., et al. (2021). Synergism of TNF-alpha and IFN-
- 667 gamma Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2
- Infection and Cytokine Shock Syndromes. Cell 184, 149-168 e117.
- 669 Kemp, H.I., Corner, E., and Colvin, L.A. (2020). Chronic pain after COVID-19: implications for
- 670 rehabilitation. Br J Anaesth *125*, 436-440.

- 671 Klingenstein, M., Klingenstein, S., Neckel, P.H., Mack, A.F., Wagner, A.P., Kleger, A., Liebau,
- 672 S., and Milazzo, A. (2020). Evidence of SARS-CoV2 Entry Protein ACE2 in the Human Nose
- and Olfactory Bulb. Cells Tissues Organs 209, 155-164.
- Ladds, E., Rushforth, A., Wieringa, S., Taylor, S., Rayner, C., Husain, L., and Greenhalgh, T.
- 675 (2020). Persistent symptoms after Covid-19: qualitative study of 114 "long Covid" patients and
- draft quality principles for services. BMC Health Serv Res 20, 1144.
- Lai, J.S., Cella, D., Choi, S., Junghaenel, D.U., Christodoulou, C., Gershon, R., and Stone, A.
- 678 (2011). How item banks and their application can influence measurement practice in
- 679 rehabilitation medicine: a PROMIS fatigue item bank example. Arch Phys Med Rehabil 92, S20-
- 680 27.
- 681 Lam, M.H., Wing, Y.K., Yu, M.W., Leung, C.M., Ma, R.C., Kong, A.P., So, W.Y., Fong, S.Y.,
- and Lam, S.P. (2009). Mental morbidities and chronic fatigue in severe acute respiratory
- 683 syndrome survivors: long-term follow-up. Arch Intern Med *169*, 2142-2147.
- Le Bert, N., Tan, A.T., Kunasegaran, K., Tham, C.Y.L., Hafezi, M., Chia, A., Chng, M.H.Y.,
- Lin, M., Tan, N., Linster, M., et al. (2020). SARS-CoV-2-specific T cell immunity in cases of
- 686 COVID-19 and SARS, and uninfected controls. Nature *584*, 457-462.
- 687 Li, Y.C., Bai, W.Z., and Hashikawa, T. (2020). The neuroinvasive potential of SARS-CoV2 may
- play a role in the respiratory failure of COVID-19 patients. J Med Virol 92, 552-555.
- 689 Liguori, C., Pierantozzi, M., Spanetta, M., Sarmati, L., Cesta, N., Iannetta, M., Ora, J., Mina,
- 690 G.G., Puxeddu, E., Balbi, O., et al. (2020). Subjective neurological symptoms frequently occur
- 691 in patients with SARS-CoV2 infection. Brain Behav Immun 88, 11-16.
- Mahase, E. (2020). Covid-19: What do we know about "long covid"? BMJ 370, m2815.

- 693 McLane, L.M., Abdel-Hakeem, M.S., and Wherry, E.J. (2019). CD8 T Cell Exhaustion During
- 694 Chronic Viral Infection and Cancer. Annu Rev Immunol *37*, 457-495.
- 695 McMahan, K., Yu, J., Mercado, N.B., Loos, C., Tostanoski, L.H., Chandrashekar, A., Liu, J.,
- 696 Peter, L., Atyeo, C., Zhu, A., et al. (2021). Correlates of protection against SARS-CoV-2 in
- 697 rhesus macaques. Nature *590*, 630-634.
- 698 Meckiff, B.J., Ramirez-Suastegui, C., Fajardo, V., Chee, S.J., Kusnadi, A., Simon, H.,
- 699 Eschweiler, S., Grifoni, A., Pelosi, E., Weiskopf, D., et al. (2020). Imbalance of Regulatory and
- 700 Cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells in COVID-19. Cell 183, 1340-1353 e1316.
- Miller, A.H. (2010). Depression and immunity: a role for T cells? Brain Behav Immun 24, 1-8.
- Mockus, T.E., Ren, H.M., Shwetank, and Lukacher, A.E. (2019). To Go or Stay: The
- 703 Development, Benefit, and Detriment of Tissue-Resident Memory CD8 T Cells during Central
- 704 Nervous System Viral Infections. Viruses 11.
- Muecksch, F., Wise, H., Batchelor, B., Squires, M., Semple, E., Richardson, C., McGuire, J.,
- 706 Clearly, S., Furrie, E., Greig, N., et al. (2021). Longitudinal Serological Analysis and
- Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. J Infect Dis
  223, 389-398.
- Mueller, S.N., Gebhardt, T., Carbone, F.R., and Heath, W.R. (2013). Memory T cell subsets,
- migration patterns, and tissue residence. Annu Rev Immunol *31*, 137-161.
- 711 Myasoedova, E., Crowson, C.S., Kremers, H.M., Therneau, T.M., and Gabriel, S.E. (2010). Is
- the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-
- 713 2007. Arthritis Rheum *62*, 1576-1582.
- Pedersen, S.F., and Ho, Y.C. (2020). SARS-CoV-2: a storm is raging. J Clin Invest *130*, 22022205.

- Peng, Y., Mentzer, A.J., Liu, G., Yao, X., Yin, Z., Dong, D., Dejnirattisai, W., Rostron, T.,
- Supasa, P., Liu, C., et al. (2020). Broad and strong memory CD4(+) and CD8(+) T cells induced
- by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol 21, 1336-
- 719 1345.
- Petersen, M.S., Kristiansen, M.F., Hanusson, K.D., Danielsen, M.E., B, A.S., Gaini, S., Strom,
- M., and Weihe, P. (2020). Long COVID in the Faroe Islands a longitudinal study among non-
- 722 hospitalized patients. Clin Infect Dis.
- Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Perez
- Marc, G., Moreira, E.D., Zerbini, C., et al. (2020). Safety and Efficacy of the BNT162b2 mRNA
- 725 Covid-19 Vaccine. N Engl J Med *383*, 2603-2615.
- Rasa, S., Nora-Krukle, Z., Henning, N., Eliassen, E., Shikova, E., Harrer, T., Scheibenbogen, C.,
- 727 Murovska, M., Prusty, B.K., and European Network on, M.C. (2018). Chronic viral infections in
- myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). J Transl Med 16, 268.
- Rodda, L.B., Netland, J., Shehata, L., Pruner, K.B., Morawski, P.A., Thouvenel, C.D., Takehara,
- 730 K.K., Eggenberger, J., Hemann, E.A., Waterman, H.R., et al. (2021). Functional SARS-CoV-2-
- 731 Specific Immune Memory Persists after Mild COVID-19. Cell *184*, 169-183 e117.
- 732 Roederer, M., Nozzi, J.L., and Nason, M.C. (2011). SPICE: exploration and analysis of post-
- cytometric complex multivariate datasets. Cytometry A 79, 167-174.
- Rosen, S.F., Ham, B., Haichin, M., Walters, I.C., Tohyama, S., Sotocinal, S.G., and Mogil, J.S.
- 735 (2019). Increased pain sensitivity and decreased opioid analgesia in T-cell-deficient mice and
- implications for sex differences. Pain *160*, 358-366.

- 737 Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L.M., Vormehr, M., Baum, A.,
- 738 Pascal, K., Quandt, J., Maurus, D., et al. (2020). COVID-19 vaccine BNT162b1 elicits human
- antibody and TH1 T cell responses. Nature *586*, *594-599*.
- Sant, A.J., DiPiazza, A.T., Nayak, J.L., Rattan, A., and Richards, K.A. (2018). CD4 T cells in
- 741 protection from influenza virus: Viral antigen specificity and functional potential. Immunol Rev
- 742 *284*, 91-105.
- 743 Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Stralin, K., Gorin, J.B., Olsson, A.,
- Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020). Robust T Cell
- 745 Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell 183, 158-
- 746 168 e114.
- 547 Shin, H., Blackburn, S.D., Blattman, J.N., and Wherry, E.J. (2007). Viral antigen and extensive
- division maintain virus-specific CD8 T cells during chronic infection. J Exp Med 204, 941-949.
- 749 Sledzinska, A., Vila de Mucha, M., Bergerhoff, K., Hotblack, A., Demane, D.F., Ghorani, E.,
- Akarca, A.U., Marzolini, M.A.V., Solomon, I., Vargas, F.A., et al. (2020). Regulatory T Cells
- 751 Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4(+) T
- 752 Cells. Immunity *52*, 151-166 e156.
- 753 Song, E., Zhang, C., Israelow, B., Lu-Culligan, A., Prado, A.V., Skriabine, S., Lu, P., Weizman,
- O.E., Liu, F., Dai, Y., *et al.* (2021). Neuroinvasion of SARS-CoV-2 in human and mouse brain. J
  Exp Med *218*.
- Sorge, R.E., Mapplebeck, J.C., Rosen, S., Beggs, S., Taves, S., Alexander, J.K., Martin, L.J.,
- Austin, J.S., Sotocinal, S.G., Chen, D., et al. (2015). Different immune cells mediate mechanical
- pain hypersensitivity in male and female mice. Nat Neurosci 18, 1081-1083.

- 759 Syed, A., Khan, A., Gosai, F., Asif, A., and Dhillon, S. (2020). Gastrointestinal pathophysiology
- of SARS-CoV2 a literature review. J Community Hosp Intern Med Perspect 10, 523-528.
- 761 Tang, E., Ekundayo, O., Peipert, J.D., Edwards, N., Bansal, A., Richardson, C., Bartlett, S.J.,
- Howell, D., Li, M., Cella, D., et al. (2019). Validation of the Patient-Reported Outcomes
- 763 Measurement Information System (PROMIS)-57 and -29 item short forms among kidney
- transplant recipients. Qual Life Res 28, 815-827.
- 765 Tebo, A.E., Fuller, M.J., Gaddis, D.E., Kojima, K., Rehani, K., and Zajac, A.J. (2005). Rapid
- recruitment of virus-specific CD8 T cells restructures immunodominance during protective
- 767 secondary responses. J Virol *79*, 12703-12713.
- Tian, Y., Babor, M., Lane, J., Schulten, V., Patil, V.S., Seumois, G., Rosales, S.L., Fu, Z.,
- Picarda, G., Burel, J., et al. (2017). Unique phenotypes and clonal expansions of human CD4
- effector memory T cells re-expressing CD45RA. Nat Commun 8, 1473.
- Tian, Y., Babor, M., Lane, J., Seumois, G., Liang, S., Goonawardhana, N.D.S., De Silva, A.D.,
- Phillips, E.J., Mallal, S.A., da Silva Antunes, R., et al. (2019). Dengue-specific CD8+ T cell
- subsets display specialized transcriptomic and TCR profiles. J Clin Invest *129*, 1727-1741.
- Tian, Y., Rong, L., Nian, W., and He, Y. (2020). Review article: gastrointestinal features in
- COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther 51, 843-851.
- Toapanta, F.R., Bernal, P.J., Kotloff, K.L., Levine, M.M., and Sztein, M.B. (2018). T cell
- 777 mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD
- 1208S in humans. J Transl Med 16, 61.
- van Doorn, A.S., Meijer, B., Frampton, C.M.A., Barclay, M.L., and de Boer, N.K.H. (2020).
- 780 Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-
- 781 oral transmission. Aliment Pharmacol Ther *52*, 1276-1288.

- Van Elslande, J., Oyaert, M., Ailliet, S., Van Ranst, M., Lorent, N., Vande Weygaerde, Y.,
- Andre, E., Lagrou, K., Vandendriessche, S., and Vermeersch, P. (2021). Longitudinal follow-up
- of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after
- 785 infection. J Clin Virol *136*, 104765.
- 786 Vehar, S., Boushra, M., Ntiamoah, P., and Biehl, M. (2021). Post-acute sequelae of SARS-CoV-
- 2 infection: Caring for the 'long-haulers'. Cleve Clin J Med 88, 267-272.
- Wang, T., Ji, Y.L., Yang, Y.Y., Xiong, X.Y., Wang, I.M., Sandford, A.J., Liang, Z.A., and He,
- J.Q. (2015). Transcriptomic profiling of peripheral blood CD4(+) T-cells in asthmatics with and
- 790 without depression. Gene *565*, 282-287.
- 791 Weintraub, S., Dikmen, S.S., Heaton, R.K., Tulsky, D.S., Zelazo, P.D., Bauer, P.J., Carlozzi,
- N.E., Slotkin, J., Blitz, D., Wallner-Allen, K., *et al.* (2013). Cognition assessment using the NIH
- 793 Toolbox. Neurology *80*, S54-64.
- 794 Weiskopf, D., Schmitz, K.S., Raadsen, M.P., Grifoni, A., Okba, N.M.A., Endeman, H., van den
- Akker, J.P.C., Molenkamp, R., Koopmans, M.P.G., van Gorp, E.C.M., et al. (2020). Phenotype
- and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory
- 797 distress syndrome. Sci Immunol 5.
- 798 Wherry, E.J. (2011). T cell exhaustion. Nat Immunol *12*, 492-499.
- 799 Wherry, E.J., Barber, D.L., Kaech, S.M., Blattman, J.N., and Ahmed, R. (2004). Antigen-
- 800 independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad
- 801 Sci U S A *101*, 16004-16009.

#### 803 Figure Legends

#### 804 Figure 1: Study design and clinical data

- A.) Flow chart describing patient populations and experimental assays for each sample. B.) Table
- showing patient demographics and neurologic symptoms. C.) PROMIS-57 patient reported
- survey T scores for CN (n=36) and CC (n=13) groups. D.) NIH Toolbox cognitive T scores for
- 808 CN (n=43). Horizontal black line represents the U.S. national average T score of 50; p values
- relative to US national average by one sample Wilcoxon signed rank test. p<0.05, p<0.005,
- 810 \*\*\*\*p<0.0001 by two-tailed Student's t test.

#### 811 Figure 2: Neuro-PASC long-haulers display altered reactivity to SARS-CoV-2 N and M

#### 812 peptides compared to healthy convalescents.

- A-B.) CN (PCR+ or seropositive neuro-PASC) and CC (PCR+ or seropositive healthy COVID
- 814 convalescent) groups display similar IFN-γ and IL-2 responses to peptides from SARS-CoV-2
- 815 Spike protein by ELISPOT. C-D.) CN samples show significantly enhanced IFN-γ responses to
- the N3 peptide pool (C) and to the M1 and M3 peptide pools (D) compared with CC or healthy
- 817 controls. E-F.) N- and M- specific IL-2 production did not significantly differ between patient
- subgroups. G.) Spike RBD IgG endpoint titer quantification for CN, CC, and HC groups. LOD is
- 819 limit of detection. Data representative of 10 experiments with all conditions plated in duplicate.
- 820 p<0.05, p<0.01, p<0.005, p<0.005, p<0.005, p<0.0001 by two-way ANOVA with Tukey's posttest.

# Figure 3: N-specific CD4<sup>+</sup> Tfh cells are more activated and S-specific CD4<sup>+</sup> T cells display

- 822 enhanced polyfunctional granzyme production in neuro-PASC long-haulers.
- A.) FACS plots show that Ag-specific CD4 Tfh from CN patients are more highly activated in
- response to N peptide pool stimulation compared with CC or HC, but less activated by M
- peptides. B). Quantification of AIM<sup>+</sup> Tfh cell activation. C-D.) N- and M-specific AIM<sup>+</sup> Tfh cell

826	percentages plotted by time sample obtained post-infection for CN and CC. No correlation was
827	found between these parameters. E.) Anti-SARS-CoV-2 nucleocapsid IgG endpoint titers for
828	CN, CC, and HC subjects shown in 3D. CN patients display significantly elevated anti-N IgG
829	titers compared with CC subjects. F.) Pie graphs show CD4 <sup>+</sup> T cells from CC patients have
830	enhanced production of granzymes A, B, & M compared with CN or HC subjects in response to
831	SARS-CoV-2 Spike protein. G.) Heatmap quantifying polyfunctionality in different categories of
832	cytokine production between groups. CC subjects produced 2-fold more granzymes A/B/M than
833	CN patients. Data combined from 6 independent experiments with CN n=35, CC n=11, and HC
834	n=9. *p<0.05 using one-way ANOVA with Bonferroni's posttest (B) or a Permutation test (E).
835	All pie graphs are showing data after subtracting background (unstimulated condition).

# Figure 4: Neuro-PASC long-haulers have decreased CD8<sup>+</sup> memory T cell activation and function compared with healthy convalescents.

A.) Selected FACS plots showing CD8 TEM cells are less activated in CN vs. CC groups after S
and N peptide pool stimulation. B.) Quantification of AIM+ CD8 TEM cells after SARS-CoV-2
peptide stimulation. C.) CD8<sup>+</sup> TEMRA cells accumulate significantly in PBMC from CN

- subjects compared with CC or HC. D.) CD8<sup>+</sup> TEMRA cells from CN patients are less activated
- by S3/4 and N pools compared with those from CC subjects. E.) Quantification of  $AIM^+ CD8^+$
- TEMRA cells from D. F.) Pie charts demonstrating that S3/4-specific CD8<sup>+</sup> TEM are polarized
- to produce more TNF- $\alpha$  in CC group while those from CN patients produce significantly more
- 845 IL-6. G.) CD8<sup>+</sup> TEMRA from CC patients are polarized towards category 2 cytokine production
- 846 in response to S3/4 stimulation compared with CN subjects. Black lines demonstrate boundaries
- of category 2 cytokine production in each group. Data combined from 5 independent
- experiments with n=35 CN, n=11 CC. \*p<0.05, \*\*p<0.01 using two-tailed Student's t test with

Welch's correction (B, C, E) or permutation test (F, G). All pie graphs are showing data after
subtracting background (unstimulated condition).

# 851 Figure 5: Clinical measures of cognitive dysfunction and depression correlate with altered

852 CD8<sup>+</sup> memory T cell function in neuro-PASC long-haulers.

A.) Higher T cell responses to N pool stimulation are positively correlated with high pain scores 853 854 in CN patients. B.) A positive trend exists between elevated N-specific IFN-y production and higher depression scores in CN patients. C.) CN patients scoring high on pain interference have 855 Spike-specific CD8<sup>+</sup> T cells producing more IL-6 than those scoring low. D.) Heatmap showing 856 857 CN with low pain scores have Spike-specific CD8<sup>+</sup> T cells producing significantly more granzymes A or B than those reporting high pain levels. E.) Pie graph to demonstrate that CN 858 patients in Q4 for depression have significantly enhanced production of granzymes A/B/M 859 compared with patients with low depression scores. F.) Heatmap demonstrating that CN patients 860 with high depression scores had Spike-specific CD8<sup>+</sup> TEM producing 3-fold higher levels of 861 862 granzymes A, B, and M or perform than those scoring low on depression. G.) Spike-specific CD8<sup>+</sup> TCM from CN patients with high scores for executive function are more polarized to 863 produce granzymes A/B/M compared with CN patients from Q1. H.) Heatmap showing Spike-864 865 specific CD8<sup>+</sup> TCM in Q1 CN patients are more polyfunctional and produce 8-10x more granzymes A/B/M and perforin than those in Q4. Data representative of 5 independent 866 experiments with n=8-9/quartile. All pie graphs showing Ag-specific cytokine production are 867 background subtracted (unstimulated conditions). \*p<0.05, \*\*p<0.01, \*\*\*\*p<0.001 using 868 Permutation tests. 869

870

# Figure 6: Spike-specific T cell responses wane within 4 months after vaccination in CC and HC subjects while remaining high in CN patients over time.

- A.) Vaccine study visit timeline. V0 was obtained before the first dose of either Pfizer or
- Moderna mRNA vaccines. V1 and V2 were conducted 3 weeks after the first and second doses,
- respectively. B.) Vaccine study subject demographics. C.) Longitudinal anti-Spike RBD IgG
- responses from V0-V4 across groups. Antibody titers are highest in CN patients and wane most
- quickly in HC subjects. D.) IFN- $\gamma$  production from Spike-specific T cells do not significantly
- 878 increase in CC and HC groups while remaining high in CN up to V4 post-vaccination. Total S-
- specific IFN- $\gamma$  SFU calculated by averaging responses from each sub-pool for each participant
- (data in Fig. S9). Data combined from 10 individual experiments with all ELISA conditions done
- in triplicate and all ELISPOT conditions plated in duplicate. \*p<0.05, \*\*p<0.01, \*\*\*p<0.005,
- \*\*\*\*p<0.0001 by two-way ANOVA with Tukey's posttest or by two-tailed Student's t test.



Patient Demographics	CN	CC	HC
Participants	56	24	31
Sex	38F, 18M	16F, 8M	19F, 12M
Race/Ethnicity	39 White 9 Hispanic 4 Asian 4 Black	15 White 6 Hispanic 3 Asian	11 White 5 Hispanic 13 Asian 2 Black
Hospitalization (%)	8 (14.3)	1 (4.2)	0 (0)
Days post-symptom onset (range)	193.4 (20-407)	155.0 (44-458)	NA
Neurologic symptoms (%)	56 (100)	0 (0)	0 (0)
Brain Fog	49 (87.5		
Fatigue	46 (82.1)		
Headache	41 (73.2)		
Dizziness	33 (58.9)		
Anosmia	35 (62.5)		
Dysgeusia	33 (58.9)		
Myalgias	34 (60.7)		

















Figure 6